Loading
companiesCompany
Serinus Biosciences
Serinus uses an explainable AI model of cancer cell biology to work out how tumours evade a drug, and to design combinations that block the escape routes.
Overview
Serinus Biosciences builds a systems-biology-primed, explainable AI platform that infers how cancer cells evolve resistance to treatment and proposes drug combinations to override the escape routes, with the aim of designing safer and more effective combination regimens that can reach patients quickly using existing molecules. Founded by MIT PhDs with advisers from the Broad Institute, Dana-Farber and UC San Diego. Work is computational and preclinical; no sourced financing rounds are recorded.
Headquarters
New York, NY, US
Funding
All startupsStartupYC S22
Investors
Type
Stage
Startup · Y Combinator Summer 2022
Website
Similar pages
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyHarmonic Discovery
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyBlank Bio
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyAlgen Biotechnologies
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyReverie Labs
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyArpeggio Bio
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.